Disease activity has been operatively defined as presence of urate deposits that lead to acute arthritis and joint damage. Every item of the pool of measures for each core domain recommended by OMERACT for trials in gout was tested for suitability in defining the concept of disease activity through a Delphi exercise. A three-step approach, similar to the methodology used for the disease activity score in rheumatoid arthritis, was applied to derive the gout activity score (GAS). Decision to change treatment was used as surrogate criterion of high disease activity. Baseline and 12-month follow-up data of 446 patients included in the KING cohort (Kick-off of the Italian Network for Gout) were used. Data included measures of all domains identified as important for trials in gout. Construct and criterion-related validity were preliminary tested using risk of flare and cross-sectional and longitudinal health assessment questionnaire score (HAQ).
C.A. Scirè, C. Viroli, M. Manara, M.A. Cimmino, M. Govoni, F. Salaffi, et al. (2013). Development and Preliminary Validation of a Candidate Disease Activity Score for Gout. ANNALS OF THE RHEUMATIC DISEASES, 72, 48-49 [10.1136/annrheumdis-2013-eular.208].
Development and Preliminary Validation of a Candidate Disease Activity Score for Gout
VIROLI, CINZIA;
2013
Abstract
Disease activity has been operatively defined as presence of urate deposits that lead to acute arthritis and joint damage. Every item of the pool of measures for each core domain recommended by OMERACT for trials in gout was tested for suitability in defining the concept of disease activity through a Delphi exercise. A three-step approach, similar to the methodology used for the disease activity score in rheumatoid arthritis, was applied to derive the gout activity score (GAS). Decision to change treatment was used as surrogate criterion of high disease activity. Baseline and 12-month follow-up data of 446 patients included in the KING cohort (Kick-off of the Italian Network for Gout) were used. Data included measures of all domains identified as important for trials in gout. Construct and criterion-related validity were preliminary tested using risk of flare and cross-sectional and longitudinal health assessment questionnaire score (HAQ).I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
